Please try another search
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.
Name | Age | Since | Title |
---|---|---|---|
Piao Yang Sun | 65 | 2003 | Chairman of the Board of Directors |
Guo Qiang Xiong | 47 | 2013 | Employee Representative Member of the Supervisory Committee |
Jie Ping Sun | 53 | 2003 | Deputy GM & Director |
Hong Bin Dai | 47 | 2003 | GM & Director |
Lian Shan Zhang | 61 | 2012 | Deputy GM & Director |
Kai Hong Yuan | 58 | 2023 | Chairman of the Supervisory Board |
Jiahong Dong | 62 | 2021 | Independent Director |
Congzhao Guo | 50 | 2020 | Director |
Jin Yun Sun | 51 | 2023 | Independent Director |
Qingsheng Zeng | 48 | 2023 | Independent Director |
Ningjun Jiang | 62 | 2023 | Deputy GM & Director |
Yu Xu | 30 | 2022 | Employee Representative Supervisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review